Summary: New research reveals that targeting the overactive mTOR cell-signaling pathway calms hyper-excitable neurons, normalizes disorganized functional brain networks, and eases repetitive behaviors within roughly two hours. Because this rapid timeframe excludes physical structural rewiring, the findings indicate that the adult brain retains significant functional plasticity despite structural developmental differences.
While rapamycin itself is unsuitable for human clinical use due to temporary efficacy, tolerance build-up, and potential toxicity, the study uncovers critical therapeutic targets focused on neuronal excitability and circuit modulation.
Key Facts
- Rapid Functional Reversal: A single dose of rapamycin improved abnormal neuronal firing, lowered seizure susceptibility, restored functional network connectivity, and reduced repetitive behaviors in adult offspring within approximately two hours.
- Functional vs. Structural Plasticity: The two-hour window for symptom alleviation demonstrates that the adult brain can functionally normalize its network activity without requiring the correction of physical, early-developmental structural differences.
- mTOR Pathway and Ion Channel Regulation: Gene activity analysis showed that rapamycin rapidly reversed the abnormal expression of genes tied to autism, epilepsy, and ion channel function, particularly in excitatory neurons.
- Maternal Immune Activation Model: Mild inflammation induced early in pregnancy led to chronic systemic and central inflammation, mild brain overgrowth, and lifelong sensory over-responsivity in mouse offspring.
- Translational Implications: Rather than advocating for direct human use of rapamycin, the findings redirect therapeutic efforts toward balancing neuronal excitation/inhibition and targeting sensory circuit neuromodulation.
Source: UCLA
A new mouse study led by UCLA Health suggests that inflammation during pregnancy can trigger autism-like changes in offspring, but also that those brain and behavior effects may be rapidly but temporarily reversible in adulthood with a short-term dose of the immunosuppressive drug rapamycin.
Even mild inflammation during mid-pregnancy has been shown to result in offspring autism-like symptoms, abnormal brain growth, seizures and heightened sensitivity to everyday sensory input that persists into adulthood.
In the study published in the journal Nature Communications, UCLA researchers found that a single dose of the drug rapamycin significantly improved brain signaling and behavior symptoms in these offspring within about two hours, a time too short to correct underlying physical brain changes created by the maternal inflammation.
The study did not identify rapamycin as a viable treatment for these symptoms in humans given its temporary effects and potential for toxicity from repeated doses. Instead, researchers said the drug’s effects revealed new therapeutic targets for the development of future treatments.
“The level of functional normalization achieved over this short time suggests new mechanisms by which possible treatments may act,” said the study’s senior author Dr. Harley Kornblum, director of the UCLA Intellectual and Developmental Disabilities Research Center in the Semel Institute for Neuroscience and Human Behavior.
“It suggests the adult brain may be more adaptable than we assumed, even when the underlying structural changes from early development are still there. This points us toward the brain’s functional circuitry, not just its physical structure, as a target for future treatment approaches.”
Previous studies have shown that offspring of mothers who experience inflammation while pregnant have a higher likelihood of developing autism-associated traits such as repetitive behaviors and difficulty with social interaction, as well as brain overgrowth and disrupted sensory processing that continue into adulthood.
Additionally, rapamycin has been shown in previous mouse autism studies to improve symptoms by suppressing an overactive pathway that signals cell growth and proliferation, known as the mTOR pathway.
What was less clear was whether these brain changes could still be modifiable in adulthood, and whether rapamycin’s benefits came from long-term structural repair or faster functional changes.
In this study, researchers exposed pregnant mice to a mild inflammatory trigger early in gestation at a dose that was too low to make the mothers significantly ill. The resulting offspring went on to develop chronic brain and body-wide inflammation, mild brain overgrowth, overactive cell-signaling in the mTOR pathway, disorganized brain functional network connectivity and behaviors associated with autism.
When researchers gave adult offspring a single dose of rapamycin, they found rapid improvement across nearly every measure: neurons that had been firing abnormally calmed down, susceptibility to seizures dropped, brain regions that had been miscommunicating reorganized into more typical patterns and repetitive behaviors and sensory over-responsivity eased. These changes occurred within roughly two hours, which was too quick to be explained by the kind of physical rewiring of brain synapses that typically takes longer.
“These results reframe how autism-associated symptoms might be treated. If the adult brain remains capable of functional normalization, then some features of autism may be successfully addressed without needing to correct underlying structural differences,” said the paper’s first author Dr. Janel Le Belle, an associate professor in the UCLA Department of Neurosurgery.
To understand the mechanisms of rapid rapamycin effects, researchers examined gene activity in brain cells before and after treatment. They found that rapamycin reversed abnormal expression of genes tied to autism, epilepsy and ion channel function, particularly in excitatory neurons, suggesting the drug works by quickly rebalancing brain cell excitability rather than by repairing structural brain differences.
The findings suggest that mTOR pathway activity, brain network organization and neuronal excitation levels as potential targets for future therapies aimed at specific autism symptoms such as sensory over-responsivity, a common but difficult-to-treat symptom of autism.
Co-senior author and professor in the UCLA Department of Neurosurgery, Dr. Neil Harris, cautioned that they also found the treatment effects to be temporary and that daily dosing produced tolerance over several weeks. This, along with rapamycin’s high potential for toxicity and the fact that these studies were performed in mice, makes it unsuitable for broad use in humans.
“This points toward new therapeutic targets like sensory circuit neuromodulation or balancing neuronal inhibition and excitation, rather than toward rapamycin itself as a treatment,” Harris said.
Key Questions Answered:
A: Exposure to maternal immune activation during gestation can cause chronic brain inflammation, overactivity in the cellular mTOR signaling pathway, altered gene expression in excitatory neurons, disrupted functional brain connectivity, and lifelong sensory sensitivity alongside autism-like behaviors.
A: Two hours is far too short a timeframe for the physical rewiring of structural synapses or brain architecture to occur. This proves that the behavioral and functional disruptions caused by maternal inflammation are driven by real-time signaling imbalances that can be functionally normalized even in adulthood.
A: No. Rapamycin carries risks of toxicity, its symptom-relieving effects in the study were temporary, and repeated daily dosing led to tolerance in mice. Its value lies in pointing scientists toward safer, more targeted therapies that rebalance neuronal excitation and sensory circuits.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this autism research news
Author: Will Houston
Source: UCLA
Contact: Will Houston – UCLA
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Acute rapamycin treatment reveals distinct mechanisms of dysfunction in a maternal inflammation mouse model” by JE Le Belle, M. C. Condro, C. Cepeda, KD Oikonomou, K. Tessema, L. Dudley, J. Schoenfield, R. Kawaguchi, D. Geschwind, AJ Silva, Z. Zhang, K. Shokat, NG Harris & HI Kornblum. Nature Communications
DOI:10.1038/s41467-026-74958-1
Abstract
Acute rapamycin treatment reveals distinct mechanisms of dysfunction in a maternal inflammation mouse model
Maternal inflammatory response (MIR) during early mouse gestation induces a cascade of physiological and behavioral changes associated with autism spectrum disorder (ASD). We have shown that mild MIR causes chronic systemic and brain inflammation, mTOR pathway activation, mild brain overgrowth with regionally specific volumetric changes, sensory processing dysregulation, and repetitive behavior abnormalities.
Prior rapamycin studies in autism models focused on chronic treatments that alter or prevent physical brain changes.
Here, we focus on acute rapamycin effects to uncover novel mTOR pathway-mediated mechanisms of dysfunction.
Within 2 hours, rapamycin rescues neuronal hyperexcitability, seizure susceptibility, functional network connectivity, brain community structure, repetitive behaviors, and sensory over-responsivity in adult MIR offspring.
These CNS-mediated effects coincide with altered expression of genes associated with ASD, ion channels, and epilepsy. Our findings demonstrate that mTOR dysregulation drives dysfunctional brain development in MIR offspring but the adult brain remains amenable to rapid functional normalization, rescuing core and comorbid ASD-associated brain and behavior phenotypes.
Restoring excitatory/inhibitory imbalance and sensory functional network modularity may be important targets for therapeutically addressing multiple ASD phenotypes.